Bioactive and Its Chondroprotective Effects in Ameliorating Osteoarthritis: A Focus on Nanoparticle Therapy

Bioactive like resveratrol, epigallocatechin gallate, curcumin, and other polyphenols often target various signalling pathways, including NFκB, TGFβ, and Wnt/β-catenin in a degenerative joint disease like osteoarthritis (OA), by executing epigenetic-modifying activities. Epigenetic modu-lation can target genes of disease pathophysiology by histone modifications, promoter DNA methylation, and non-coding RNA expression, some of which are directly involved but less ex-plored in OA. OA patients often explore options that can improve the quality of their life in ad-dition to existing treatment with nonsteroidal anti-inflammatory drugs (NSAIDs). Although bi-oactive and natural compounds exhibited therapeutic potential against OA, several disadvantages loom, like insolubility and poor bioavailability. Nanoformulated bioactives promise a better way to alleviate OA since they also control systemic events, including metabolic, immunological, and inflammatory responses, by modulating host gut microbiota that can regulate OA pathogenesis. Recent data suggest gut dysbiosis in OA. However, limited evidence is available on the role of bioactive as epigenetic and gut modulators in ameliorating OA. Moreover, the question of whether polyphenolic bioactive modulates gut microbial response that results in epigenetic-controlling activities of OA pathogenesis is not known. This narrative review explored the interplay of nanoformulated bioactive and host gut microbiota on chondrocyte growth, metabolism, and epigenetic alteration linked with OA progression and pathogenesis.